 CRANBURY, N.J., Dec. 01, 2020 GLOBE NEWSWIRE -- Rafael Pharmaceuticals, Inc. Rafael or the Company, a leader in the growing field of cancer metabolism-based therapeutics, today announced it will initiate a Phase 2 clinical trial of CPI-613devimistat in combination with hydroxychloroquine in patients with clear cell sarcoma of soft tissue. In partnership with Saras Cure and Sarcoma Alliance for Research through Collaboration SARC , Rafael will begin enrolling patients into the Simon two-stage design trial at sites across the United States. 